Literature DB >> 23243156

The revised IPSS is a powerful tool to evaluate the outcome of MDS patients treated with azacitidine: the GFM experience.

Mathilde Lamarque, Sophie Raynaud, Raphael Itzykson, Sylvain Thepot, Bruno Quesnel, Francois Dreyfus, Odile Beyne Rauzy, Pascal Turlure, Norbert Vey, Christian Recher, Caroline Dartigeas, Laurence Legros, Jacques Delaunay, Sorin Visanica, Aspasia Stamatoullas, Pierre Fenaux, Lionel Adès.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23243156     DOI： 10.1182/blood-2012-09-453555

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  21 in total

1.  Impact of the revised International Prognostic Scoring System on the outcome of patients with acute myeloid leukemia with or without antecedent myelodysplastic syndrome.

Authors:  F Stölzel; M Kramer; B Mohr; M Wermke; M Bornhäuser; G Ehninger; M Schaich; U Platzbecker
Journal:  Leukemia       Date:  2013-11-25       Impact factor: 11.528

2.  Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromes.

Authors:  Amer M Zeidan; Ju-Whei Lee; Thomas Prebet; Peter Greenberg; Zhuoxin Sun; Mark Juckett; Mitchell R Smith; Elisabeth Paietta; Janice Gabrilove; Harry P Erba; Martin S Tallman; Steven D Gore
Journal:  Br J Haematol       Date:  2014-04-09       Impact factor: 6.998

3.  Myelodysplastic syndromes, version 2.2015.

Authors:  Peter L Greenberg; Richard M Stone; Rafael Bejar; John M Bennett; Clara D Bloomfield; Uma Borate; Carlos M De Castro; H Joachim Deeg; Amy E DeZern; Amir T Fathi; Olga Frankfurt; Karin Gaensler; Guillermo Garcia-Manero; Elizabeth A Griffiths; David Head; Virginia Klimek; Rami Komrokji; Lisa A Kujawski; Lori J Maness; Margaret R O'Donnell; Daniel A Pollyea; Bart Scott; Paul J Shami; Brady L Stein; Peter Westervelt; Benton Wheeler; Dorothy A Shead; Courtney Smith
Journal:  J Natl Compr Canc Netw       Date:  2015-03       Impact factor: 11.908

Review 4.  Molecular Testing in Myelodysplastic Syndromes for the Practicing Oncologist: Will the Progress Fulfill the Promise?

Authors:  Aziz Nazha; Mikkael A Sekeres; Steven D Gore; Amer M Zeidan
Journal:  Oncologist       Date:  2015-07-20

Review 5.  MDS prognostic scoring systems – past, present, and future.

Authors:  Brian A Jonas; Peter L Greenberg
Journal:  Best Pract Res Clin Haematol       Date:  2014-11-11       Impact factor: 3.020

6.  Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS.

Authors:  Amer M Zeidan; Ju-Whei Lee; Thomas Prebet; Peter Greenberg; Zhuoxin Sun; Mark Juckett; Mitchell R Smith; Elisabeth Paietta; Janice Gabrilove; Harry P Erba; Rhett P Katterling; Martin S Tallman; Steven D Gore
Journal:  Br J Haematol       Date:  2014-07-04       Impact factor: 6.998

Review 7.  Improving Prognostic Modeling in Myelodysplastic Syndromes.

Authors:  Aziz Nazha; Mikkael A Sekeres
Journal:  Curr Hematol Malig Rep       Date:  2016-12       Impact factor: 3.952

8.  Validation of the revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes.

Authors:  Asmita Mishra; Maria Corrales-Yepez; Najla Al Ali; Mohamed Kharfan-Dabaja; Eric Padron; Ling Zhang; Pearlie K Epling-Burnette; Javier Pinilla-Ibarz; Jeffrey E Lancet; Alan F List; Rami S Komrokji
Journal:  Am J Hematol       Date:  2013-05-30       Impact factor: 10.047

Review 9.  There's risk, and then there's risk: The latest clinical prognostic risk stratification models in myelodysplastic syndromes.

Authors:  Amer M Zeidan; Rami S Komrokji
Journal:  Curr Hematol Malig Rep       Date:  2013-12       Impact factor: 3.952

10.  Therapeutic Options for Patients who are not Eligible for Intensive Chemotherapy.

Authors:  Elihu Estey
Journal:  Mediterr J Hematol Infect Dis       Date:  2013-07-12       Impact factor: 2.576
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.